Personalised base editing: what an individual-patient result can show

Personalised base editing aims to change a specific DNA base at a chosen genomic site using an editor designed around a patient’s variant. It is an emerging treatment strategy, not a service that can be assumed suitable for any rare genetic condition. A successful early case can establish that a carefully designed approach is feasible without proving long-term safety, a cure or broad availability.

This guide explains the science and how to read an individual-patient report. It does not provide a treatment protocol. The clinical decisions, manufacturing and safety assessments require a specialist research and regulatory pathway.

A candidate edit must reach the relevant cells, produce the intended molecular effect and demonstrate clinical benefit with adequate safety assessment.

What is being edited?

DNA base pairs include A–T and C–G. Two established classes of base editor are adenine base editors, which can produce an A–T to G–C change, and cytosine base editors, which can produce a C–G to T–A change. Which change appears in a clinical report also depends on the strand used for the description. Other editing technologies exist; these two examples are not a catalogue of every experimental editor.

Classic base-editing designs do not require a programmed double-strand DNA break at the target, although nicking of one strand can be part of the mechanism. That distinction does not mean that unintended changes are impossible. The original adenine base-editing study explains the molecular principle; the Addgene technical overview compares the established editor classes.

Personalisation involves more than the gene name

Question	Why it matters
Is the variant truly disease-causing?	Editing an uncertain finding does not establish that it explains the illness.
Is the required DNA change compatible with the editor?	The base conversion, sequence context and targeting constraints matter.
Which cells need treatment?	A delivery system that reaches liver cells may not solve a brain or muscle disorder.
How much correction is likely to help?	The relevant threshold depends on the biology; editing every cell is not a universal requirement or a universal achievement.
What else could be changed?	Nearby bystander edits and changes at unintended sites require assessment.
What damage is already present?	Correcting a molecular defect does not necessarily reverse established organ injury.

The published CPS1 case: what was actually reported?

In May 2025, investigators reported treatment of one infant with severe carbamoyl-phosphate synthetase 1 deficiency, a urea-cycle disorder. They developed a patient-specific adenine base editor delivered in lipid nanoparticles to liver cells. The initial report described two infusions at about seven and eight months of age. Over seven weeks after the first infusion, the child tolerated more dietary protein and a reduction in nitrogen-scavenger medication. The authors called for longer follow-up. See the original NEJM report and NIH’s account of the work.

That paragraph describes the initial publication, not a current clinical update about the child. It is evidence about one carefully selected case over a defined interval. It cannot establish the probability of benefit for another variant, another organ or another person.

A fictional example: same gene, different feasibility

Two patients have variants in the same disease gene. One has a single-base substitution that fits an available editing strategy in cells the delivery system can reach. The other has a large deletion. A method designed to change one base would not replace the missing stretch of DNA.

Even for the first patient, compatibility on paper is only the beginning. The team still needs evidence on editing efficiency, unintended changes, delivery, manufacturing quality and the clinical balance of potential benefit and harm. “The gene can be edited” is not equivalent to “this person has an available treatment.”

How to read an N-of-1 report

Write down the actual intervention. Distinguish base editing, gene addition, RNA treatment and other approaches.
Identify the baseline. What was happening before treatment, and how variable was the condition?
List the observed outcomes. Separate laboratory changes, medication changes, symptoms and organ function.
Record concurrent care. Diet, supportive treatment, infections and other interventions can affect observations.
Mark the follow-up boundary. A short initial report cannot establish lifelong durability.
Read the safety evidence. Distinguish preclinical tests, events observed in the patient and risks that remain uncertain.
State the narrow conclusion. Explain what happened in this person without assigning a population success rate.

What does safety assessment need to address?

FDA guidance for somatic genome-editing products discusses product quality, nonclinical assessment and clinical study design. Relevant concerns include unintended changes at the intended site, off-target editing and uncertain long-term effects. These assessments are product-specific; an editor’s general description cannot substitute for evidence about the actual candidate treatment. Read the FDA guidance.

A clinical response also does not prove that every relevant cell was corrected. Conversely, an editing percentage in an experimental model is not itself a patient outcome. A careful paper connects delivery, molecular effects and clinical observations while acknowledging what was not measured.

Questions for a specialist conversation

Is the molecular diagnosis established, and is the variant suitable for this kind of approach?
Is there an actual registered study or authorised pathway, rather than only a laboratory idea?
Which tissue must be reached, and what evidence supports the proposed delivery?
What established treatment or supportive care remains important?
Which outcomes and risks would be monitored, and for how long?
What costs, travel, follow-up obligations and uncertainties would participation involve?

Somatic treatment targets cells in the treated person; it should not be confused with editing embryos or creating a heritable change. For interpreting evidence, use the gene-therapy trial guide and the durability worksheet. The research tools directory helps locate original publications and registered studies.